MEDICAL COMMUNITY

“Green light” to Lilly’s monoclonal antibody to migraine

INDUSTRY, MEDICAL COMMUNITY, News, PATIENTS, PATIENTS ASSOCIATIONS / By

Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab ( Emgality ) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month . Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes […]

“Green light” to Lilly’s monoclonal antibody to migraine Read More »

Migraine Atlas by AEMICE

MEDICAL COMMUNITY, News, PATIENTS ASSOCIATIONS, POLICY MAKERS / By

AEMICE together with Universidad de Sevilla (Seville University) and Novartis and a scientific committee of expert neurologists has created the Migraine Atlas by AEMICE 2018 which reflects the real situation of the 4.5 million people who suffer from migraine in Spain! Unlike other studies “Migraine Atlas” includes the patients and also their families perspective about their condition,

Migraine Atlas by AEMICE Read More »

Master on Headache Disorders

MEDICAL COMMUNITY, News, PATIENTS ASSOCIATIONS / By

Copenhagen University is now offering a Master on Headache Disorders. It´s a continuing professional development programme for healthcare professionals. The programme of the Master on Headache Disorders requires a minimum of 6 individual visits to Copenhagen, Denmark over a two-year period: Modules 1 to 4 are organized with an e-learning self-study period followed by one week

Master on Headache Disorders Read More »

Women and Migrain

MEDICAL COMMUNITY, News, PATIENTS / By

Women and Migraine Women and migraine: Estrogen may explain why women suffer more often migraines Spanish researchers have discovered that the role of this sex hormone around the trigeminal nerve could be key in migraine episodes, which could explain why woman suffer from them more often.  Sex hormones could play a key role in the

Women and Migrain Read More »

Why are migraine patients skipping effective behavioral treatments?

MEDICAL COMMUNITY, News, PATIENTS / By

Effective behavioral treatments for migraine are being eschewed by a significant number of sufferers, according to a new study led by headache researchers at NYU School of Medicine. Researchers found that about half of migraine patients who were referred by a headache center for specific behavioral treatment did not follow through with therapy. This occurred

Why are migraine patients skipping effective behavioral treatments? Read More »

First monoclonal antibody therapy for prevention of migraine

INDUSTRY, MEDICAL COMMUNITY, News / By

First monoclonal antibody therapy for prevention of Migraine Aimovig recommended for marketing authorization 01/06/2018 The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Aimovig (erenumab), the first human monoclonal antibody therapy for prevention of migraine. Aimovig belongs to a new class of medicines that work by blocking the activity

First monoclonal antibody therapy for prevention of migraine Read More »

Arnold Neuralgia/Recurrent occipital pain cause

MEDICAL COMMUNITY, News, PATIENTS / By

Recurrent, troublesome occipital pain associated with muscular tension is known as Arnold’s neuralgia, a strange condition. The condition of peripheral nerves can produce the pain of varying intensity as a reflex mechanism, depending on the degree of damage being considered. Some anatomical locations are often associated with these syndromes, with the exception of the occipital

Arnold Neuralgia/Recurrent occipital pain cause Read More »

logo-emha-footer
MENU
LASTEST NEWS
ALL NEWS
SOCIAL
Facebook Instagram Twitter Youtube
Scroll to Top

FOR YOU

Working together we can achieve a better future for all patients living with migraine.

Facebook Instagram Twitter Youtube
Search
Close this search box.
Facebook Instagram Twitter Youtube